PureTech Health (PRTC) Long-Term Deferred Tax (2019 - 2024)
PureTech Health (PRTC) reported Long-Term Deferred Tax of $6.8 million for Q2 2024, up 4673.24% quarter-over-quarter from $142000.0 in Q4 2019.
PureTech Health (PRTC) Long-Term Deferred Tax (2019 - 2024) Analysis & Trends
PureTech Health (PRTC) has 2 years of Long-Term Deferred Tax data on file, last reported at $6.8 million in Q2 2024.
- Long-Term Deferred Tax for Q2 2024 came in at $6.8 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was $6.8 million (changed N/A YoY), and the FY2019 annual result was $142000.0, changed N/A from the prior year.
- Long-Term Deferred Tax climbed to $6.8 million in Q2 2024 per PRTC's latest filing, from $142000.0 in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $6.8 million in Q2 2024 and troughed at $6.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 6.78 Mn |
| Dec 31, 2019 | 142,000.00 |